



Why Partner With Us



Local Expertise

Trusted UAE-based pharmaceutical partner



Proven Performance

Proven track record with global and regional companies



Comprehensive Capabilities

End-to-end capabilities: development to commercialization



Regulatory Strength

Regulatory excellence across multiple markets



Partner-Focused Approach

Flexible, partner-centric approach

Manufacturing Capacity

2 Billion

Tablets
(including bilayer)



500 Million

Capsules




High-volume

Liquid
Production




Global Market Presence





Business Development Strengths



Quality & Compliance

01



Advanced QC
and
Microbiology
laboratories

02



Robust quality
systems and
governance

03



Consistent
regulatory
success across
markets

Global and Regional Partners



- Full scale manufacturing
- New product development
- Contract manufacturing for Tablets and Capsules



- Full scale manufacturing
- Contract manufacturing for Tablets and Capsules
- Market: CANADA, US, LATAM and MENA



- Contract manufacturing for Tablets and Capsules



Production Equipment

Machine	No. of Resources	Critical Equipment	Capacity
Granulation			
WET GRANULATION 125L (30 – 60 KG)	2	RMG – TAPASYA	150 LTS
		FBD – ACG	125 LTS
WET GRANULATION 500L (200 – 490 KG)	2	RMG – TAPASYA	800 LTS
		FBD – ACG	500 LTS
DRY GRANULATION (50 – 450 KG)	1	ROLL COMPACTOR – ALEXANDER WERK WP 200	200 KG / HR
DIRECT MIX (5 – 400 KG)	4	BIN BLENDER	50/75/110/310/500/750/1000 LTS
Compression			
COMPRESSION D TOOLING	2	GEA COURTOY – MODUL D [53 STATION]	MAX OUTPUT/HR 537,420 TABLETS
COMPRESSION B TOOLING	2	GEA COURTOY – R150E [30 STATION]	MAX OUTPUT/HR 216000 TABLETS

Production Equipment

Machine	No. of Resources	Critical Equipment	Capacity
Coating			
COATING 175"	1	175 LITS - ACG	60 - 100 KG / LOT
COATING 700"	2	700 LITS - ACG	147 - 490 KG / LOT
24 / 56" INTERCHANGEABLE PAN	1	TCM QUEST 24/56" - ACG	8 - 36 KG / LOT
Capsule Filling			
CAPSULE FILLING	2	AF 40T / 90 T- ACG PAM	40,000/90000 - CAPS/HR
Packaging			
Blister Packing - Tablet / Capsule			
BLISTER PACKING	1	BP602 / CP120	100 BLISTER / MIN
BLISTER PACKING	3	HM400 / HP200	400 BLISTERS / MIN
Bottle - Tablet / Capsule			
BOTTLE PACKING CVC	1	CVC -TIAWAN / CVC 1220-2	120 BPM
Bottle - Liquid			
LIQUID -BOTTLE	1	COMAS ITALY	120 BPM

Quality Assurance (QA)

Independent Quality function governing all Quality operations at site consists of QA & QC.

QMS

1. Document Control and Management
2. Change Control
3. Deviations Management
4. CAPA Management
5. Complaint Handling
6. Internal Audit
7. Vendor Qualification
8. Product Recall
9. Field Alerts
10. Pharmacovigilance

cGMP

1. Training
2. Annual Product Review
3. SOP/Spec/Protocol Preparation and Review
4. Batch Release

IPQA

1. Batch Record Review
2. Line Clearance
3. Online GMP Inspection

Qualification/Validations

1. Equipment Qualification and Validations
2. Process Evaluation Batches
3. Process Validations
4. Cleaning Validations

Analytical Compliance

1. ADS Review (RM, PM, In Process and FP)
2. Stability Review
3. Material Release
4. OOS/OOT/Incidents

Data Management Systems – SAP

1. Materials Movement
2. Electronic Batch Records (eBR)
3. CAPA
4. Change Control System
5. Equipment Maintenance
6. Instrument Calibration



Quality Control (QC)

- Quality Control unit responsible for sampling, testing, approval and rejection of all raw materials, packing materials and testing of in process and finished products.
- All HPLC and GC chromatographic instruments are equipped with EMPOWER3 software and the standalone instruments (UV, IR, Titrator, etc.) are equipped with 21 CFR complaint software.

QC Systems

1. Sampling and testing of RM/PM/IP/FP
2. Training
3. QC Instruments Calibration
4. Stability Studies
5. Analytical Method Validations/Method Transfer/Verification
6. Control Samples Management

QC Key Instruments

1. HPLC with EMPOWER3 – 13 Nos
2. UPLC with EMPOWER3 – 01 No
3. GC with EMPOWER3 – 01 No
4. AAS – 02 Nos
5. UV – 01 No
6. IR – 01 No
7. Stability Chambers – 05 Nos
8. Incubators – 06 Nos
9. KF Titrator – 01 No
10. Malvern Particle Size Analyzer – 01 No

Microbiology

1. Area, Environment Monitoring
2. Water Sampling and Testing
3. Microbiological testing of the RM/PM/FP



Therapeutic Portfolio



Acute and Chronic
Care Segments



Cardio-metabolic,
Neurology,
Gastrointestinal,
Anti-infectives



Strong presence
in migraine and
specialty
segments

Acute & Chronic Care Segments

Oseltamivir

Acute, uncomplicated influenza in patients 2 weeks of age and older



Azithromycin

Acute bacterial exacerbations of chronic bronchitis due to *Haemophilus influenzae*, *Moraxella catarrhalis*, or *Streptococcus pneumoniae*



Vitamin B1, B6, B12

Deficiency of B Complex vitamins



Acute & Chronic Care Segments

Ibuprofen

Relieves minor aches and pains due to headache, backache, the common cold, minor arthritis pain, toothache, menstrual cramps, and muscular aches, and temporarily reduces fever



Paracetamol

Treat mild to moderate pain (from headaches, menstrual periods, toothaches, backaches, osteoarthritis, or cold/flu aches and pains) and to reduce fever



Cardio-metabolic, Neurology, Gastrointestinal, Anti-infectives

Atorvastatin

Prevent cardiovascular disease in those at high risk and to treat abnormal lipid levels



Rosuvastatin

Hypercholesterolemia, hyperlipidemia, mixed dyslipidemia, primary dysbetalipoproteinemia, hypertriglyceridemia, and prevention of cardiovascular disease



Amlodipine, Valsartan

Treat high blood pressure (hypertension) and heart failure



Clopidogrel

Reduce risk of heart disease, stroke, Co Rx with Aspirin



Strong presence in migraine and specialty segments

Frovatriptan

The longest half-life among all triptans for the acute treatment of migraine with or without aura in adults, with superior efficacy against menstrual migraine.



Vonoprazan

Used to treat acid-related gastrointestinal disorders and for Helicobacter pylori eradication in combination therapy.



Rosuvastatin, Ezetimibe

Used for the management of hypercholesterolemia to reduce elevated cholesterol levels and lower the risk of cardiovascular events



Future Growth Strategy



Expansion into
biologics and
oncology



Entry into complex
injectables



Strengthening global
partnerships

